NASDAQ:INKT MiNK Therapeutics (INKT) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free INKT Stock Alerts $0.93 +0.06 (+6.92%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.88▼$0.9350-Day Range$0.86▼$1.5652-Week Range$0.75▼$3.34Volume32,348 shsAverage Volume195,198 shsMarket Capitalization$32.18 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get MiNK Therapeutics alerts: Email Address MiNK Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside870.4% Upside$9.00 Price TargetShort InterestHealthy0.49% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.59) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.84 out of 5 starsMedical Sector607th out of 913 stocksBiological Products, Except Diagnostic Industry98th out of 152 stocks 3.5 Analyst's Opinion Consensus RatingMiNK Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMiNK Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.49% of the float of MiNK Therapeutics has been sold short.Short Interest Ratio / Days to CoverMiNK Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MiNK Therapeutics has recently increased by 18.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMiNK Therapeutics does not currently pay a dividend.Dividend GrowthMiNK Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INKT. Previous Next 1.7 News and Social Media Coverage News SentimentMiNK Therapeutics has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for MiNK Therapeutics this week, compared to 0 articles on an average week.Search Interest2 people have searched for INKT on MarketBeat in the last 30 days. MarketBeat Follows6 people have added MiNK Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MiNK Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.81% of the stock of MiNK Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.87% of the stock of MiNK Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MiNK Therapeutics are expected to grow in the coming year, from ($0.59) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MiNK Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MiNK Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About MiNK Therapeutics Stock (NASDAQ:INKT)MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Read More INKT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INKT Stock News HeadlinesApril 11, 2024 | finance.yahoo.comThis MiNK Therapeutics Insider Increased Their Holding In The Last YearApril 8, 2024 | globenewswire.comMiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACRApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 25, 2024 | markets.businessinsider.comBuy Rating for MiNK Therapeutics Amidst Promising AGENT-797 Progress and Strategic Financial MovesMarch 22, 2024 | insidermonkey.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | markets.businessinsider.comPromising Clinical Progress and Market Potential for MiNK Therapeutics’ agenT-797 in Gastric Cancer StudyMarch 21, 2024 | investorplace.comINKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023March 21, 2024 | globenewswire.comMiNK Reports Fourth Quarter and Year-End 2023 ResultsApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 20, 2024 | benzinga.comEarnings Outlook For MiNK TherapeuticsMarch 8, 2024 | finanznachrichten.deMiNK Therapeutics: MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024March 7, 2024 | globenewswire.comMiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial ReportMarch 6, 2024 | globenewswire.comMiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024February 24, 2024 | msn.comCell therapy could help patients with ARDS from severe Covid-19, study involving ARU showsFebruary 14, 2024 | finance.yahoo.comFirst Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and BalstilimabFebruary 6, 2024 | finance.yahoo.comMiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature CommunicationsJanuary 30, 2024 | finance.yahoo.comMiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in OncogeneDecember 20, 2023 | markets.businessinsider.comImmunoScape, MiNK Therapeutics Join To Develop Next-generation TCR TherapiesDecember 20, 2023 | finance.yahoo.comImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic DevelopmentNovember 22, 2023 | morningstar.comMiNK Therapeutics Inc INKTNovember 9, 2023 | msn.comMiNK Therapeutics GAAP EPS of -$0.15November 9, 2023 | finance.yahoo.comMiNK Therapeutics Reports Third Quarter 2023 ResultsNovember 9, 2023 | finance.yahoo.comMiNK Therapeutics Inc (INKT) Reports Q3 2023 Results: Clinical Progress Amid Financial ChallengesNovember 3, 2023 | finance.yahoo.comMiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023November 3, 2023 | finance.yahoo.comMiNK Therapeutics Insider Ups Holding During YearOctober 30, 2023 | finance.yahoo.comMiNK to Provide Third Quarter 2023 Financial Report and Corporate UpdateSeptember 27, 2023 | finance.yahoo.comMiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023See More Headlines Receive INKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/27/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:INKT CUSIPN/A CIK1840229 Webwww.minktherapeutics.com Phone212-994-8250FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$9.00 Low Stock Price Target$9.00 Potential Upside/Downside+870.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,460,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-220.64% Debt Debt-to-Equity RatioN/A Current Ratio0.32 Quick Ratio0.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.52) per share Price / Book-1.78Miscellaneous Outstanding Shares34,700,000Free Float28,519,000Market Cap$32.18 million OptionableNo Data Beta0.13 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Garo H. Armen Ph.D. (Age 71)Executive Chairman Dr. Jennifer S. Buell Ph.D. (Age 48)President, CEO & Director Comp: $812.78kDr. Marcus Antonius van Dijk Ph.D. (Age 62)Chief Scientific Officer Comp: $369.92kMs. Christine M. Klaskin (Age 58)Treasurer Comp: $27.24kJoy Zhou Ph.D.Vice President & Head of CMCKey CompetitorsAchilles TherapeuticsNASDAQ:ACHLSurrozenNASDAQ:SRZNCortexymeNASDAQ:CRTXWindtree TherapeuticsNASDAQ:WINTIN8bioNASDAQ:INABView All CompetitorsInsidersAgenus IncBought 429 shares on 10/16/2023Total: $471.90 ($1.10/share)Agenus IncBought 3,173 shares on 10/12/2023Total: $3,490.30 ($1.10/share)Agenus IncBought 15,001 shares on 10/4/2023Total: $16,351.09 ($1.09/share)Agenus IncBought 12,808 shares on 8/28/2023Total: $18,571.60 ($1.45/share)Agenus IncBought 170,244 shares on 8/24/2023Total: $262,175.76 ($1.54/share)View All Insider Transactions INKT Stock Analysis - Frequently Asked Questions Should I buy or sell MiNK Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MiNK Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INKT shares. View INKT analyst ratings or view top-rated stocks. What is MiNK Therapeutics' stock price target for 2024? 2 analysts have issued twelve-month target prices for MiNK Therapeutics' stock. Their INKT share price targets range from $9.00 to $9.00. On average, they expect the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 870.4% from the stock's current price. View analysts price targets for INKT or view top-rated stocks among Wall Street analysts. How have INKT shares performed in 2024? MiNK Therapeutics' stock was trading at $1.07 at the start of the year. Since then, INKT shares have decreased by 13.3% and is now trading at $0.9275. View the best growth stocks for 2024 here. Are investors shorting MiNK Therapeutics? MiNK Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 48,500 shares, an increase of 18.0% from the March 31st total of 41,100 shares. Based on an average daily trading volume, of 97,500 shares, the short-interest ratio is presently 0.5 days. Approximately 0.5% of the shares of the stock are sold short. View MiNK Therapeutics' Short Interest. When is MiNK Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our INKT earnings forecast. How were MiNK Therapeutics' earnings last quarter? MiNK Therapeutics, Inc. (NASDAQ:INKT) announced its quarterly earnings results on Thursday, March, 21st. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01. When did MiNK Therapeutics IPO? MiNK Therapeutics (INKT) raised $43 million in an initial public offering (IPO) on Friday, October 15th 2021. The company issued 3,333,334 shares at $12.00-$14.00 per share. How do I buy shares of MiNK Therapeutics? Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INKT) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
